Rocket Pharmaceuticals, Inc. Investment Income, Amortization of Premium
Rocket Pharmaceuticals, Inc. (RCKT) reported Investment Income, Amortization of Premium of $0 for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeAmortizationOfPremium · last filed 2019-05-09
- Rocket Pharmaceuticals, Inc. investment income, amortization of premium for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. investment income, amortization of premium for the quarter ending 2018-03-31 was $12.00K.
- Rocket Pharmaceuticals, Inc. investment income, amortization of premium for the quarter ending 2017-12-31 was $33.00K, a 45.90% decline year-over-year.
- Rocket Pharmaceuticals, Inc. investment income, amortization of premium for the quarter ending 2017-09-30 was $51.00K, a 1.92% decline year-over-year.
- Rocket Pharmaceuticals, Inc. investment income, amortization of premium for fiscal 2017 was $217.00K, a 3.56% decline from fiscal 2016.
- Rocket Pharmaceuticals, Inc. investment income, amortization of premium for fiscal 2016 was $225.00K, a 200.00% increase from fiscal 2015.
- Rocket Pharmaceuticals, Inc. investment income, amortization of premium for fiscal 2015 was $75.00K.
| Period end | Investment Income, Amortization of Premium 3 month | Investment Income, Amortization of Premium 3 month as first filed | Investment Income, Amortization of Premium 6 month | Investment Income, Amortization of Premium 9 month | Investment Income, Amortization of Premium 12 month |
|---|---|---|---|---|---|
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 | ||||
| 2018-03-31 | $12.00K 10-Q · filed 2019-05-09 | $45.00K derived: sum of 2 quarters · filed 2019-05-09 | $96.00K derived: sum of 3 quarters · filed 2019-05-09 | $229.00K derived: sum of 4 quarters · filed 2019-05-09 | |
| 2017-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $84.00K derived: sum of 2 quarters · filed 2018-03-07 | $217.00K derived: sum of 3 quarters · filed 2018-03-07 | $217.00K 10-K · filed 2018-03-07 | |
| 2017-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $184.00K derived: sum of 2 quarters · filed 2017-11-08 | $184.00K 10-Q · filed 2017-11-08 | $245.00K derived: sum of 4 quarters · filed 2018-05-11 | |
| 2017-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $133.00K 10-Q · filed 2017-08-03 | $194.00K derived: sum of 3 quarters · filed 2018-05-11 | $246.00K derived: sum of 4 quarters · filed 2018-05-11 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-11 | $71.00K 10-Q · filed 2017-05-10 | $61.00K derived: sum of 2 quarters · filed 2018-05-11 | $113.00K derived: sum of 3 quarters · filed 2018-05-11 | $182.00K derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $113.00K derived: sum of 2 quarters · filed 2018-03-07 | $182.00K derived: sum of 3 quarters · filed 2018-03-07 | $225.00K 10-K · filed 2018-03-07 | |
| 2016-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $121.00K derived: sum of 2 quarters · filed 2017-11-08 | $164.00K 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $112.00K 10-Q · filed 2017-08-03 | |||
| 2016-03-31 | $43.00K 10-Q · filed 2017-05-10 | ||||
| 2015-12-31 | $75.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |